Pitolisant oxalate is a potent and selective inverse agonist of nonimidazole at the recombinant human histamine H3 receptor with Ki of 0.16 nM.

H3 receptor:0.16 nM (Ki), H3 receptor:1.5 nM (EC50)

Pitolisant behaves as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50 value of 1.5 nM and an intrinsic activity ~50% higher than that of ciproxifan.

The administration of Pitolisantat a single dose of 10 mg/kg 30 min before a single dose of Olanzapine (2 mg/kg b.w.) also significantly affects immobility time in the FST. Subsequent administration of the aforementioned drug sequence in mice statistically significantly increases the duration of immobility in comparison to the time determined in the control group in the FST. It decreased locomotor activity as well[3]